Novo Nordisk’s weight-loss medication Wegovy (semaglutide) was approved in Japan in March. While it skipped the May round of reimbursement listing, physicians eagerly await the arrival of what would be the first new obesity drug in three decades. Other companies…
HOME > TOP STORIES
TOP STORIES
-
REGULATORY Expert Panel Agrees on Need for Generic Industry Shakeup, Company Criteria Floated
February 16, 2023
-
BUSINESS As Global Race Heats Up for RAS Drugs, Japan Players Joining Fray with New Modalities
February 15, 2023
-
BUSINESS BMS Mulls CAR-T Manufacturing in Japan, Definitive Plans Expected by Year-End
February 14, 2023
-
BUSINESS Asahi Kasei to Push Teribone Auto-Injector, but AG Remains an Option: President
February 13, 2023
-
REGULATORY Japan Cancels 140 Million-Plus Dose Order of Novavax’s COVID Vaccine
February 13, 2023
-
REGULATORY Expert Panel’s Proposal Likely to Involve “2-Stage” Reform, Touch on Funding Too: Chairman
February 10, 2023
-
BUSINESS Kyowa Kirin Has No Plans to Launch Biosame of G-Lasta: President
February 10, 2023
-
REGULATORY Chuikyo Talks Over Sales Criteria to Trigger Possible Xocova Re-Pricing; Is 3-Month-Based Estimate an Overestimate?
February 9, 2023
-
BUSINESS CSL Behring Soon to Launch Home Delivery Service for Hemophilia Therapies
February 8, 2023
-
BUSINESS Next Astellas CEO Says Weathering Xtandi Cliff Is His Biggest Mission
February 7, 2023
-
REGULATORY Expert Panel Member Sakamaki Wants Pricing Overhaul to Push Generic Industry Consolidation
February 6, 2023
-
BUSINESS Astellas EVP Okamura to Become CEO in April
February 6, 2023
-
BUSINESS Mitsubishi Chemical Calls It Quit for Medicago, COVID Jab
February 6, 2023
-
BUSINESS Chugai’s Sales Hit 1-Trillion-Yen Mark in 2022 on New Launches, Ronapreve
February 3, 2023
-
REGULATORY Chuikyo OKs Use of Multiple Comparators to Price Xocova, Upping of Reduction Cap Mooted for Re-Pricing
February 2, 2023
-
BUSINESS Daiichi Sankyo Taps CFO Okuzawa as New President, Set to Continue ADC Drive
February 1, 2023
-
BUSINESS Shionogi Logs Record Profits as Xocova Nets 100 Billion Yen from Govt Purchase: April-December
January 31, 2023
-
BUSINESS Lecanemab Earns Priority Review in Japan, Eisai Aims for Approval by Year-End
January 31, 2023
-
REGULATORY Panel OKs Japan’s First Abortion Pill, but Upper Organ to Review It Again after Public Comments
January 30, 2023
-
REGULATORY It’s Official: Japan to Downgrade COVID-19 Severity Status on May 8
January 30, 2023
ページ
President Joe Biden enacted the Inflation Reduction Act (IRA) on August 16, 2022, significantly affecting Medicare prescription drug coverage and introducing targeted changes to Medicaid, the Children’s Health Insurance Program, and private health insurance. In January 2023, the Centers for…
Japan’s health ministry on April 27 presented an outline of a report to be compiled next month by its key…
A key Japanese reimbursement policy panel on December 16 approved the government-backed plan for the FY2023 “off-year” drug price revision.…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…